Therapeutic immunomodulation in systemic vasculitis: Taking stock

Joint Bone Spine

Volumn 80, Issue 4, 2013, Pages 374-379

  Puéchal, Xavier ^a   Guillevin, Loïc ^a  

^a Université Paris Descartes ^*  (France)

Author keywords

Biotherapies; Cytokine antagonists; Experimental drugs; Immunomodulation; Monoclonal antibodies; Rituximab; TNF antagonists; Treatment; Vasculitis

Indexed keywords

ABATACEPT; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 6; MEPOLIZUMAB; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; TOCILIZUMAB; VIDARABINE;

ANTIVIRAL THERAPY; AORTA ARCH SYNDROME; B LYMPHOCYTE ACTIVATION; CORONARY ARTERY ANEURYSM; CRYOGLOBULINEMIA; DENDRITIC CELL; EOSINOPHILIC GRANULOMA; FOLLOW UP; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN PARVOVIRUS B19; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INCIDENCE; INFECTION RISK; JC VIRUS; KIDNEY FAILURE; LEG ULCER; LUNG HEMORRHAGE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POLYARTERITIS; POLYARTERITIS NODOSA; PRIMARY POLYARTERITIS NODOSA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID VASCULITIS; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SYSTEMIC VASCULITIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 84880331047     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.10.023     Document Type: Short Survey

References (63)

1. Jennette JC, Falk RJ, Bacon PA, et al. Revised International Chapel Hill Consensus Conference Nomenclature of the Vasculitides. Arthritis Rheum 2012. [Epub ahead of print]. doi:10.1002/art.37715.
2. http://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp%3Fid=c_608140.
3. Jones R.B., Cohen Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
4. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
5. Thurner L., Müller A., Cérutti M., et al. Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. J Autoimmun 2011, 36:87-90.
6. Guillevin L., Pagnoux C., Karras A., et al. Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (abstract). Arthritis Rheum 2012, 64:S706.
7. Guerry M.J., Brogan P., Bruce I.N., et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2012, 51:634-643.
8. http://www.cri-net.com/recherche/fichesPratiques/get_fiche.asp%3Flang=rituximab%26chap=19_Utilisation_du_rituximab_dans_les_maladies_auto-immunes.
9. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012; [Epub ahead of print]. doi:10.1002/art.34583.
10. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): A single-center ten-year experience. Arthritis Rheum 2012; [Epub ahead of print]. doi:10.1002/art.34584.
11. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012, 64:3043-3051.
12. Palazzo E., Yahia S.A. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine 2012, 79:351-355.
13. Mukhtyar C., Luqmani R. Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis. Ann Rheum Dis 2005, 64:iv31-iv36.
14. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
15. Booth A., Harper L., Hammad T., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717-721.
16. de Menthon M., Cohen P., Pagnoux C., et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow-up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 2011, 29:S63-S71.
17. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361.
18. Jayne D.R., Chapel H., Adu D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000, 93:433-439.
19. Martinez V., Cohen P., Pagnoux C., et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008, 58:308-317.
20. Jayne D.R., Gaskin G., Rasmussen R., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180-2188.
21. Lockwood C., Thiru S., Isaacs J., et al. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993, 1:1620-1622.
22. Walsh M., Chaudhry A., Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (Campath-1H). Ann Rheum Dis 2008, 67:1322-1327.
23. Bouldouyre M.A., Cohen P., Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009, 68:606.
24. Metzler C., Schnabel A., Gross W.L., et al. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008, 26:S35-S40.
25. Metzler C., Csernok E., Gross W.L., et al. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 2010, 28:24-30.
26. Kim S., Marigowda G., Oren E., et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:1336-1343.
27. Moosig F., Gross W.L., Herrmann K., et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011, 155:341-343.
28. De Vita S., Quartuccio L., Isola M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:843-853.
29. Sneller M.C., Hu Z., Langford C.A. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:835-842.
30. Petrogrande M., De Vita S., Zignego A.L., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10:444-454.
31. Sène D., Ghillani-Dalbin P., Amoura Z., et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60:3848-3855.
32. Saadoun D., Rosenzwajg M., Joly F., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011, 365:2067-2077.
33. Guillevin L., Lhote F., Léon A., et al. Treatment of polyarteritis nodosa related to hepatitis B virus with short-term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993, 20:289-298.
34. Guillevin L., Lhote F., Sauvaget F., et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994, 53:334-337.
35. Guillevin L., Lhote F., Cohen P., et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995, 74:238-253.
36. Guillevin L., Mahr A., Cohen P., et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004, 51:482-487.
37. Saadoun D., Terrier B., Semoun O., et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res 2011, 63:427-435.
38. Viguier M., Guillevin L., Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulins. N Engl J Med 2001, 344:1481-1482.
39. Newburger J.W., Takahashi M., Burns J.C., et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986, 315:341-347.
40. Newburger J.W., Takahashi M., Beiser A.S., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633-1639.
41. Son M.B., Newburger J.W. Management of Kawasaki disease: corticosteroids revisited. Lancet 2012, 379:1571-1572.
42. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
43. Martínez-Taboada V.M., Rodríguez-Valverde V., Carreño L., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
44. Mariette X., Baron G., Hachulla E., et al. Results of a randomized controlled study of adalimumab for steroid sparing in patients with giant-cell arteritis (abstract). Arthritis Rheum 2011, 60:S589-S590.
45. Masson C. Therapeutic approach to giant cell arteritis. Joint Bone Spine 2012, 79:219-227.
46. Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012. [Epub ahead of print]. doi:10.1002/art.34647.
47. Samson M., Audia S., Janikashvili N., et al. Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:2499-2503.
48. Seitz M., Reichenbach S., Bonel H.M., et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Swiss Med Wkly 2011, 141:w13156.
49. Beyer C., Axmann R., Sahinbegovic E., et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Ann Rheum Dis 2011, 70:1874-1875.
50. Salvarani C., Magnani L., Catanoso M., et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012, 51:151-156.
51. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012. [Epub ahead of print]. doi:10.1002/acr.21750.
52. Hoffman G.S., Merkel P.A., Brasington R.D., et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004, 50:2296-2304.
53. Mekinian A., Néel A., Sibilia J., et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012, 51:882-886.
54. Unger L., Kayser M., Nüsslein H.G. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003, 62:587-588.
55. Puéchal X., Miceli-Richard C., Mejjad O., et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008, 67:880-884.
56. Assmann G., Pfreundschuh M., Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol 2010, 28:81-83.
57. Puéchal X., Gottenberg J.E., Berthelot J.M., et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res 2012, 64:331-339.
58. Sumida K., Ubara Y., Takemoto F., et al. Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol 2011, 29:S133.
59. Fujii W., Kohno M., Ishino H., et al. The rapid efficacy of abatacept in a patient with rheumatoid vasculitis. Mod Rheumatol 2012, 22:630-634.
60. Hind C.R., Paraskevakou H., Lockwood C.M., et al. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1983, 1:263-265.
61. Arzoo K., Sadeghi S., Liebman H.A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002, 61:922-924.
62. Clatworthy M.R., Wallin E.F., Jayne D.R. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008, 359:768-769.
63. Nishimura K., Saegusa J., Kawano S., et al. Tumor necrosis factor-α inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis. J Rheumatol 2012, 39:1904-1905.